Literature DB >> 10397535

Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection.

S Staprans1, N Marlowe, D Glidden, T Novakovic-Agopian, R M Grant, M Heyes, F Aweeka, S Deeks, R W Price.   

Abstract

OBJECTIVES: To compare the kinetics and magnitude of HIV-1 RNA responses to antiretroviral therapy (ART) in the cerebrospinal fluid (CSF) and plasma.
DESIGN: Repeated lumbar punctures (LPs) were performed after the initiation or change in ART in 15 HIV-1-infected subjects, with the focus on two phases of response: an acute phase within the first 11 days, for which crude estimates of viral RNA half-lives and decay rates were derived and CSF:plasma relative decay ratios quantitatively analysed; and a longer-term phase beyond 4 weeks that was descriptively assessed.
RESULTS: In 13 subjects studied during the acute phase, the crude HIV-1 RNA half-life was longer (median 2.0 compared with 1.9 days), the decay rate slower (median 0.13 compared with 0.16 log10 copies/day) and, most notably, the variability greater (intraquartile range of half-life 1.8-4.3 compared with 1.7-2.1 days) in the CSF than in the plasma. A slower decay in the CSF correlated with lower initial blood CD4 T lymphocyte counts (P = 0.001). Seven of 11 subjects studied at 4 weeks or later, including some with slower acute-phase CSF responses, showed greater or more durable viral suppression in the CSF.
CONCLUSION: Divergent acute-phase viral kinetics in the CSF and plasma, and proportionally greater long-term decrements in CSF HIV-1 RNA in slow early-responders or poor overall plasma responders indicate variable compartmentalization of CSF infection, consistent with a model of two prototypes of CSF infection: short-lived, transitory infection that predominates in early HIV-1 infection and longer-lived, more autonomous CSF infection predominating in late HIV-1 infection. Additional studies will be needed to define more precisely the acute and longer-term CSF kinetics in different clinical settings and to assess this model.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10397535     DOI: 10.1097/00002030-199906180-00008

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  44 in total

1.  Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy.

Authors:  C M Marra; D Lockhart; J R Zunt; M Perrin; R W Coombs; A C Collier
Journal:  Neurology       Date:  2003-04-22       Impact factor: 9.910

Review 2.  Thinking about HIV: the intersection of virus, neuroinflammation and cognitive dysfunction.

Authors:  K Grovit-Ferbas; M E Harris-White
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

3.  Transmigration of macrophages across the choroid plexus epithelium in response to the feline immunodeficiency virus.

Authors:  Rick B Meeker; D C Bragg; Winona Poulton; Lola Hudson
Journal:  Cell Tissue Res       Date:  2012-01-27       Impact factor: 5.249

4.  Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients.

Authors:  Dianne Langford; Jennifer Marquie-Beck; Sergio de Almeida; Deborah Lazzaretto; Scott Letendre; Igor Grant; J Allen McCutchan; Eliezer Masliah; Ronald J Ellis
Journal:  J Neurovirol       Date:  2006-04       Impact factor: 2.643

5.  Quantification of entry phenotypes of macrophage-tropic HIV-1 across a wide range of CD4 densities.

Authors:  Sarah B Joseph; Kathryn T Arrildt; Adrienne E Swanstrom; Gretja Schnell; Benhur Lee; James A Hoxie; Ronald Swanstrom
Journal:  J Virol       Date:  2013-12-04       Impact factor: 5.103

6.  Impact of short-term combined antiretroviral therapy on brain virus burden in simian immunodeficiency virus-infected and CD8+ lymphocyte-depleted rhesus macaques.

Authors:  Lakshmanan Annamalai; Veena Bhaskar; Douglas R Pauley; Heather Knight; Kenneth Williams; Margaret Lentz; Eva Ratai; Susan V Westmoreland; R Gilberto González; Shawn P O'Neil
Journal:  Am J Pathol       Date:  2010-07-01       Impact factor: 4.307

7.  Quantitation of human immunodeficiency virus type 1 RNA in different biological compartments.

Authors:  R N Shepard; J Schock; K Robertson; D C Shugars; J Dyer; P Vernazza; C Hall; M S Cohen; S A Fiscus
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

8.  Cerebrospinal fluid HIV viral load in different phases of HIV-associated brain disease.

Authors:  Hans-Jürgen von Giesen; Ortwin Adams; Hubertus Köller; Gabriele Arendt
Journal:  J Neurol       Date:  2005-03-06       Impact factor: 4.849

9.  Giant cell encephalitis and microglial infection with mucosally transmitted simian-human immunodeficiency virus SHIVSF162P3N in rhesus macaques.

Authors:  Carole Harbison; Ke Zhuang; Agegnehu Gettie; James Blanchard; Heather Knight; Peter Didier; Cecilia Cheng-Mayer; Susan Westmoreland
Journal:  J Neurovirol       Date:  2014-01-25       Impact factor: 2.643

10.  Major coexisting human immunodeficiency virus type 1 env gene subpopulations in the peripheral blood are produced by cells with similar turnover rates and show little evidence of genetic compartmentalization.

Authors:  William L Ince; Patrick R Harrington; Gretja L Schnell; Milloni Patel-Chhabra; Christina L Burch; Prema Menezes; Richard W Price; Joseph J Eron; Ronald I Swanstrom
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.